Analysts Expect Zafgen Inc (ZFGN) Will Post Earnings of -$0.40 Per Share
Wall Street analysts predict that Zafgen Inc (NASDAQ:ZFGN) will report earnings of ($0.40) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Zafgen’s earnings. The highest EPS estimate is ($0.36) and the lowest is ($0.44). Zafgen posted earnings per share of ($0.58) in the same quarter last year, which indicates a positive year-over-year growth rate of 31%. The company is scheduled to issue its next quarterly earnings report on Tuesday, May 14th.
On average, analysts expect that Zafgen will report full-year earnings of ($1.60) per share for the current fiscal year, with EPS estimates ranging from ($1.93) to ($1.31). For the next fiscal year, analysts expect that the company will report earnings of ($1.71) per share, with EPS estimates ranging from ($2.34) to ($1.15). Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Zafgen.
Zafgen (NASDAQ:ZFGN) last issued its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.04.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wedbush Securities Inc. bought a new stake in Zafgen in the 1st quarter worth about $96,000. Geode Capital Management LLC increased its holdings in Zafgen by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 420,983 shares of the biopharmaceutical company’s stock worth $2,083,000 after buying an additional 22,235 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Zafgen by 2.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 904,194 shares of the biopharmaceutical company’s stock worth $4,476,000 after buying an additional 21,423 shares in the last quarter. 683 Capital Management LLC increased its holdings in Zafgen by 7.7% in the 4th quarter. 683 Capital Management LLC now owns 1,400,000 shares of the biopharmaceutical company’s stock worth $6,930,000 after buying an additional 100,000 shares in the last quarter. Finally, Great Point Partners LLC increased its holdings in Zafgen by 6.1% in the 4th quarter. Great Point Partners LLC now owns 3,598,392 shares of the biopharmaceutical company’s stock worth $17,812,000 after buying an additional 207,007 shares in the last quarter. Institutional investors own 86.74% of the company’s stock.
Shares of NASDAQ:ZFGN opened at $2.59 on Friday. Zafgen has a 1-year low of $2.57 and a 1-year high of $12.35. The company has a quick ratio of 9.12, a current ratio of 9.12 and a debt-to-equity ratio of 0.16. The firm has a market cap of $96.65 million, a PE ratio of -1.36 and a beta of -0.42.
Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.